Evidence map›Paper›PMID 42305256›Full record

ArticleKidney international reports2026

Optimization of a Target Antigen Diagnostic Pathway for Membranous Nephropathy.

Wangyang Li, Cheng Huang, Shuling Yue, Qingqing Rao, Xun Qin, Haofei Hu, Lin Wang, Ji Cen, Ricong Xu, Haiying Song and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Wangyang LiDepartment of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Cheng HuangDepartment of Nephrology, Hechi People's Hospital, Hechi, Guangxi, China.
Shuling YueRenal Pathology Laboratory, Guangzhou KingMed Diagnostics Group Co., Ltd., Guangzhou, Guangdong, China.
Qingqing RaoDepartment of Nephrology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, Anhui, China.
Xun QinDepartment of Nephrology, Hechi People's Hospital, Hechi, Guangxi, China.
Haofei HuDepartment of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Lin WangRenal Pathology Laboratory, Guangzhou KingMed Diagnostics Group Co., Ltd., Guangzhou, Guangdong, China.
Ji CenDepartment of Nephrology, Hechi People's Hospital, Hechi, Guangxi, China.
Ricong XuDepartment of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Haiying SongDepartment of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Yi XuDepartment of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Xiuli ZhangDepartment of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Xiangyang WangDepartment of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Xu DongDepartment of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Yuan ChengDepartment of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Qijun WanDepartment of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The recent Mayo Clinic consensus proposed a target antigen-based diagnostic pathway for membranous nephropathy (MN), recommending testing for neural epidermal growth factor-like 1 (NELL1) following a negative phospholipase A Methods: This dual-center retrospective study included 816 patients with PLA2R staining on renal biopsy (2008-2023). PLA2R-negative patients with atypical features and available tissue underwent comprehensive testing for thrombospondin type-1 domain-containing 7A (THSD7A), NELL1, exostosin1/2 (EXT1/2), semaphorin 3B (SEMA3B), and protocadherin 7 (PCDH7). Testing efficiency was simulated in a subcohort comprising all PLA2R-positive patients and PLA2R-negative patients with complete antigen data. Results: PLA2R positivity was 73.90%. Among PLA2R-negative patients ( Conclusion: In Chinese PLA2R-negative patients with atypical features, EXT1/2 and NELL1 are the predominant antigens. Sequential testing by local prevalence (PLA2R → EXT1/2 → NELL1) is resource-efficient, whereas concurrent testing offers time savings. This practical framework aids diagnostic optimization, especially for patients with an autoimmune phenotype.

Indexed as

membranous nephropathyprecision medicinetarget antigen

Identifiers

PMID42305256
PMCPMC13265659

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.